Exec Chat: Dexcom Continues To Evolve Blood Glucose Measurement Market
Executive Summary
In an interview with Medtech Insight, Dexcom CEO Kevin Sayer discussed his views on the blood glucose measurement market, how he thinks it will change, and Dexcom’s responsibilities to patients, regulators and payors.
You may also be interested in...
How Viable Is The Future Of The “Traditional” CGM?
Flagship products like Dexcom’s G7 and Abbott’s FreeStyle Libre 3 offer currently unrivalled accuracy of blood glucose measurement. However, as truly noninvasive technologies improve, the future basis for these companies’ growth is on shaky ground.
Dexcom Rumored To Be In Talks To Acquire Insulet
Dexcom may be planning to purchase Insulet to enter the insulin pump market and transform itself into a diabetes tech giant.
Exec Chat: Dexcom’s CEO Bullish On Year Ahead With G7 CGM Launch, Dexcom One CGM Expansion
In an interview with Medtech Insight following the J.P. Morgan Health Care Conference, Dexcom CEO Kevin Sayer discussed marketing plans for the next-generation G7 continuous glucose monitoring system and for the simpler CGM, Dexcom One, and outlined plans ahead.